Literature DB >> 10648907

Effect of the topoisomerase-II inhibitor etoposide on meiotic recombination in male mice.

L B Russell1, P R Hunsicker, A M Hack, T Ashley.   

Abstract

Unlike other chemicals that have been tested in mammalian germ cells, the type-II topoisomerase inhibitor etoposide exhibits significant mutagenicity in primary spermatocytes. Because this is the cell stage during which meiotic recombination normally occurs, and because topoisomerases play a role in recombination, we studied the effect of etoposide on crossing-over in male mice. Exposure to those meiotic prophase stages (probably early to mid-pachytene) during which specific-locus deletion mutations can be induced resulted in decreased crossing-over in the p-Tyr(c) interval of mouse chromosome 7. Accompanying cytological studies with fluorescent antibodies indicated that while there was no detectable effect on the number of recombination nodules (MLH1 foci), there were marked changes in the stage of appearance and localization of RAD51 and RPA proteins. These temporal and spatial protein patterns suggest the formation of multiple lesions in the DNA after MLH1 has already disappeared from spermatocytes. Since etoposide blocks religation of the cut made by type II topoisomerases, repair of DNA damage may result in rejoining of the original DNA strands, undoing the reciprocal exchange that had already occurred and resulting in reduced crossing-over despite a normal frequency of MLH1 foci. Crossing-over could conceivably be affected differentially in different chromosomal regions. If, however, the predominant action of etoposide is to decrease homologous meiotic recombination, the chemical could be expected to increase nondisjunction, an event associated with human genetic risk. Three periods in spermatogenesis respond to etoposide in different ways. Exposure of (a) late differentiating spermatogonia (and, possibly, preleptotene spermatocytes) results in cell death; (b) early- to mid-pachytene induces specific-locus deletions and crossover reduction; and, (c) late pachytene-through-diakinesis leads to genetically unbalanced conceptuses as a result of clastogenic damage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648907     DOI: 10.1016/s1383-5718(99)00185-0

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Etoposide induces heritable chromosomal aberrations and aneuploidy during male meiosis in the mouse.

Authors:  F Marchetti; J B Bishop; X Lowe; W M Generoso; J Hozier; A J Wyrobek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Impact of the chemotherapy cocktail used to treat testicular cancer on the gene expression profile of germ cells from male Brown-Norway rats.

Authors:  Geraldine Delbès; Donovan Chan; Pirjo Pakarinen; Jacquetta M Trasler; Barbara F Hales; Bernard Robaire
Journal:  Biol Reprod       Date:  2008-11-05       Impact factor: 4.285

3.  Topoisomerases Modulate the Timing of Meiotic DNA Breakage and Chromosome Morphogenesis in Saccharomyces cerevisiae.

Authors:  Jonna Heldrich; Xiaoji Sun; Luis A Vale-Silva; Tovah E Markowitz; Andreas Hochwagen
Journal:  Genetics       Date:  2020-03-09       Impact factor: 4.562

4.  Protective role of N-acetylcysteine (NAC) on human sperm exposed to etoposide.

Authors:  João Baetas; Ana Rabaça; Ana Gonçalves; Alberto Barros; Mário Sousa; Rosália Sá
Journal:  Basic Clin Androl       Date:  2019-02-07

5.  GCNA Interacts with Spartan and Topoisomerase II to Regulate Genome Stability.

Authors:  Gregoriy A Dokshin; Gregory M Davis; Ashley D Sawle; Matthew D Eldridge; Peter K Nicholls; Taylin E Gourley; Katherine A Romer; Luke W Molesworth; Hannah R Tatnell; Ahmet R Ozturk; Dirk G de Rooij; Gregory J Hannon; David C Page; Craig C Mello; Michelle A Carmell
Journal:  Dev Cell       Date:  2019-12-12       Impact factor: 12.270

6.  Etoposide damages female germ cells in the developing ovary.

Authors:  Agnes Stefansdottir; Zoe C Johnston; Nicola Powles-Glover; Richard A Anderson; Ian R Adams; Norah Spears
Journal:  BMC Cancer       Date:  2016-08-11       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.